la terapia dell’ipersecrezione ormonale: l’acromegalia
TRANSCRIPT
![Page 1: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/1.jpg)
Andrea LaniaEndocrinology and Andrology Unit
Pituitary UnitNET Multidisciplinary Group
Istituto Clinico HumanitasDepartment of Biomedical Sciences
Humanitas University
La terapia dell’ipersecrezione ormonale: l’acromegalia
![Page 2: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/2.jpg)
mortalità e co-morbidità
![Page 3: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/3.jpg)
![Page 4: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/4.jpg)
![Page 5: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/5.jpg)
Surgery is associated with higher remission rate (at the longest follow up; 67 vs 45%)higher remission rates in GH levels
2629 patients
![Page 6: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/6.jpg)
…più della metà dei pazienti è trattata da centri a basso volume…
![Page 7: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/7.jpg)
Pre-surgery: GH levels less than 2.5 in 14%; IGF-I levels normalized in 10%Postsurgical SSA treatment lowered GH levels <2.5 in 56%normalized IGF-I levels in 55%.
![Page 8: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/8.jpg)
Ipogonadismo
Iposurrenalismo
Ipotiroidismo
Post-intervento
«new» normalizzati
5,8% 32%
7,5% 41%
5,6% 35%
![Page 9: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/9.jpg)
![Page 10: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/10.jpg)
IGF-I normalization on cabergoline therapy was predicted in univariate analysis by the baseline IGF-I concentration
IGF-1 normalization(% of patients)
53292526
IGF-1 (% of ULN)
150150-199200-249
>250
JCEM 2011
![Page 11: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/11.jpg)
11
Melmed et al. TEM 2010
GiG0
cAMP
[Ca2+]MAPK
secretion proliferation
apoptosis
AC
K+ Ca2+
Sst2 & 5
SST2&5
PTP Sst 3
Sst2
Sst5
2&
Octreotide LAR (10-20-30 mg)Lanreotide Autogel (60-90-120 mg)
![Page 12: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/12.jpg)
IGF-I normalization occurred in a greater proportion of secondary octreotide LAR- vs. primary octreotide-treated subjects
Biochemical control (GH<2.5+normal IGF-1) in:
48.6 % of patients in pasireotide LAR45.7 % of patients in octreotide LAR
![Page 13: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/13.jpg)
A higher proportion of microadenoma patients had GH levels ≤2.5 and <1.0 μg/L at all time points compared withmacroadenoma patients
IGF-1 normalization + GH ≤2.5 μg/L in 65.0% (M12) and 54.8% (M24)IGF-1 normalization + GH < 1.0 μg/L in 51.7% (M12) and 42.9% (M24)
![Page 14: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/14.jpg)
Pts with tumor shrinkage(%)
53
66
Octreotide sc
Octreotide LAR
Tumor shrinkage(%)
53
66
Octreotide sc
Octreotide LAR
the shrinkage effect of octreotide correlates with duration of therapy
the clinical relevance of tumorshrinkage may be greater in macroadenomas compared withmicroadenomas
![Page 15: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/15.jpg)
Primary treatment with lanreotideAutogel 120 mg every 28 days provides tumor volume reduction in 62.9% of patients at 1 year.
These reductions were evident in 54.1% of patients by the first postbaseline visit at 3 months
significant reduction if > 20%
Response at 3 months can predict long-term response
![Page 16: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/16.jpg)
16
A Consensus Statement on acromegaly therapeuticoutcomesShlomo Melmed et al. Nature Reviews Endocrinology 14, 552–561 (2018)
![Page 17: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/17.jpg)
![Page 18: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/18.jpg)
18
Cabergolina(terapia combinata)
Sandret & Chanson, JCEM 2011
77 pazienti
Normalizzazione IGF-I: 52% dei pz
Risposta correlata a:
•livelli basali di IGF-I (0.74; P0.001)
Nessuna correlazione con il dosaggio di
cabergolina , la durata del trattamento
e i livelli basali di PRL
![Page 19: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/19.jpg)
Pasireotide
![Page 20: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/20.jpg)
biochemical control in 27% of patients
biochemical control in 31.3% of patients
biochemical control in 48.6% of patients
Hyperglycemia related AEs in up to 60%
![Page 21: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/21.jpg)
IGF-1 normalized in 19 patients, IGF-1 between 1-1.2 × ULN was reached in five, and in additional two patients IGF-1 was significantly suppressed
deterioration of glucose control in 63% of patients, requiring initiation or intensification of antidiabetic treatment
Biochemical control (2 h mean GH <2.5 μg/L and normalised IGF-1 at 24 weeks) 15% patients in the pasireotide-LAR 40 mg group and 20% patients in the pasireotide-LAR 60 mg group
![Page 22: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/22.jpg)
Sparsely granulated adenomas responded better to pasireotide compared to densely granulated ones
![Page 23: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/23.jpg)
Pegvisomant
Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration.
Serum insulin and glucose concentrations were significantly decreased (p<0·05)
Van der Lely et al. 2001 Lancet
The French ACROSTUDY
The Spanish ACROSTUDY
The German ACROSTUDY
Thr Italian ACROSTUDY
IGF-1 normalization
63%
67%
58%
70%
Ann Endocrinol 2015 Dec;76(6):664-70
Pituitary. 2016 Apr;19(2):127-37
Eur J Endocrinol. 2009 Nov;161 Suppl 1:S3-S10
Endocrine. 2015 Feb;48(1):334-41
![Page 24: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/24.jpg)
Responders: 73.3%
While most patients (55.5%) received the medication as monotherapy at the start of PEGV treatment, over time that percentage decreased and combination therapy was increasingly employed …
AEs considered treatment related wereexperienced by 16.1% of patients: • lipohypertrophy (n = 31), • liver test elevations (n = 30), • gastro-intestinal disorders (n = 26), • asthenia (n = 9), • headache (n = 7), • lipodystrophy (n = 5)
…Among patients who had an increase as per local reading, the central reading confirmed an increase in 24% of cases
Tumor size
Increased
6.8%
Decreased
16.8%
Unchanged
16.8%
![Page 25: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/25.jpg)
Disease control was associated with lower baseline GH, IGF-1 and IGF-1 xULN
PEGV resistance was associated with higher BMI
Diabetic patients needed higher doses of PEGV than non-diabetic ones
![Page 26: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/26.jpg)
Terapia combinata
![Page 27: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/27.jpg)
When pegvisomant started:
41.9 % pegvisomant monotherapy50.4 % SSA + Pegvisomant5 % SSA + Pegvisomant + cabergoline2.6 % Pegvisomant + cabergoline
![Page 28: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/28.jpg)
Terapia combinata SMS-PEG: possibili vantaggi
Ulteriore controllo del metabolismo glicemico
Riduzione del dosaggio settimanale di PEG
Miglior controllo della crescita tumorale
Neggers et al. 2010 Nat Rev Endocrinology
![Page 29: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/29.jpg)
Group PEG+SSA showed:
• higher IGF-I and GH levels
• higher rates residual tumor tissue at baseline
• more substantial responses to SSA monotherapy
• worse outcomes (IGF-I normalization rates, final
IGF-I levels)
![Page 30: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/30.jpg)
30
IGF-I levels returned to normal in 4 patients (28%) at the end of the study.In addition, some decline in IGF-I levels was observed in a further 5 patients.
All patients whose IGF-I levels returned to normal had previously been irradiated
Better response to combinationtherapy related to:
• lower baseline IGF-I• female gender • lower body weight • higher PRL levels
![Page 31: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/31.jpg)
![Page 32: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/32.jpg)
At 20 years of follow‐up, control was seen in all on acromegaly‐specific medication (n = 12) and 75% of those off medication
53% of patients developed new hypopituitarism at a median follow‐up of 146 monthsThe development of first onset of hypopituitarism occurred as late as 20 years after treatment
The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively
Mean time to durable remission after SRS 38 mo
development of ≥1 new endocrinopathy in 26%
Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission
Time for 50% to achieve control on medication: 3 yearsoff medications: 7.4 years
![Page 33: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/33.jpg)
![Page 34: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/34.jpg)
ICH Endocrinologia e Andrologia Medica
Nazarena BetellaWalter VenaFlaminia CarroneEmilia BiamontiSara Piccini
Paolo ColomboAlessandro PizzocaroElisabetta Lavezzi
Carlo FedeliAlberto TresoldiLiborio Vacalluzzo
Giulia TarantolaLivin Nurcin
Endo LabEleonora VitaliIlena Boemi
ICH Pituitary Unit
![Page 35: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/35.jpg)
![Page 36: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/36.jpg)
Group A: patients from centers treating more than 15 ptsGroup B: patients from centers treating less than 15 pts
different control rates possibly related to:• the occurrence of a more
aggressive disease in many patients of group A
• dose titration
![Page 37: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/37.jpg)
37
![Page 38: La terapia dell’ipersecrezione ormonale: l’acromegalia](https://reader035.vdocuments.us/reader035/viewer/2022070700/62c3cf44f177a25c4406e029/html5/thumbnails/38.jpg)
Pituitary centers of excellence